Literature DB >> 23643669

Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.

Roberto Romero, Frank Z Stanczyk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23643669      PMCID： PMC4120746          DOI： 10.1016/j.ajog.2013.04.027

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN： 0002-9378            Impact factor:   8.661


× No keyword cloud information.
  72 in total

1.  Collagen remodelling in the guinea-pig uterine cervix at term is associated with a decrease in progesterone receptor expression.

Authors:  H A Rodríguez; L Kass; J Varayoud; J G Ramos; H H Ortega; M Durando; M Muñoz-De-Toro; E H Luque
Journal:  Mol Hum Reprod       Date:  2003-12       Impact factor: 4.025

2.  Was the preterm birth rate in the placebo group too high in the Meis MFMU Network trial of 17-OHPC?

Authors:  Jay D Iams
Journal:  Am J Obstet Gynecol       Date:  2010-05       Impact factor: 8.661

Review 3.  Dynamics of cervical remodeling during pregnancy and parturition: mechanisms and current concepts.

Authors:  R Ann Word; Xiang-Hong Li; Michael Hnat; Kelley Carrick
Journal:  Semin Reprod Med       Date:  2007-01       Impact factor: 1.303

4.  17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.

Authors:  William A Grobman; Elizabeth A Thom; Catherine Y Spong; Jay D Iams; George R Saade; Brian M Mercer; Alan T N Tita; Dwight J Rouse; Yoram Sorokin; Ronald J Wapner; Kenneth J Leveno; Sean Blackwell; M Sean Esplin; Jorge E Tolosa; John M Thorp; Steve N Caritis; J Peter Van Dorsten
Journal:  Am J Obstet Gynecol       Date:  2012-09-17       Impact factor: 8.661

5.  Forgotten "father of progesterone".

Authors:  Thomas Kerenyi
Journal:  Am J Obstet Gynecol       Date:  2009-12-30       Impact factor: 8.661

6.  Prevention of preterm birth by progestational agents: what are the molecular mechanisms?

Authors:  Christopher Nold; Monique Maubert; Lauren Anton; Steven Yellon; Michal A Elovitz
Journal:  Am J Obstet Gynecol       Date:  2013-03       Impact factor: 8.661

7.  Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions.

Authors:  Nicole K Ruddock; Shao-Qing Shi; Sangeeta Jain; Gradie Moore; Gary D V Hankins; Roberto Romero; Robert E Garfield
Journal:  Am J Obstet Gynecol       Date:  2008-10       Impact factor: 8.661

8.  The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time.

Authors:  Celeste P Durnwald; Courtney D Lynch; Hetty Walker; Jay D Iams
Journal:  Am J Obstet Gynecol       Date:  2009-08-28       Impact factor: 8.661

9.  Cervical ripening in humans: potential roles of estrogen, progesterone, and insulin-like growth factor-I.

Authors:  Y Stjernholm; L Sahlin; S Akerberg; A Elinder; H A Eriksson; A Malmström; G Ekman
Journal:  Am J Obstet Gynecol       Date:  1996-03       Impact factor: 8.661

10.  Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice.

Authors:  Juan M Gonzalez; Claus-Werner Franzke; Fengyuan Yang; Roberto Romero; Guillermina Girardi
Journal:  Am J Pathol       Date:  2011-06-12       Impact factor: 4.307
View more
  18 in total

1.  Vaginal progesterone for prevention of preterm birth in asymptomatic high-risk women with a normal cervical length: a systematic review and meta-analysis protocol.

Authors:  Kimberley P Williams; Liam McAuliffe; Rosanna Diacci; Anne-Marie Aubin; Ashad Issah; Carol Wang; Jason Phung; Craig E Pennell
Journal:  Syst Rev       Date:  2021-05-21

Review 2.  What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.

Authors:  Steve N Caritis; Maisa N Feghali; William A Grobman; Dwight J Rouse
Journal:  Semin Perinatol       Date:  2016-04-19       Impact factor: 3.300

Review 3.  Progesterone to prevent spontaneous preterm birth.

Authors:  Roberto Romero; Lami Yeo; Piya Chaemsaithong; Tinnakorn Chaiworapongsa; Sonia S Hassan
Journal:  Semin Fetal Neonatal Med       Date:  2013-12-05       Impact factor: 3.926

4.  17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.

Authors:  David B Nelson; Donald D McIntire; Jeffrey McDonald; John Gard; Paula Turrichi; Kenneth J Leveno
Journal:  Am J Obstet Gynecol       Date:  2017-02-20       Impact factor: 8.661

5.  Pharmacokinetics of vaginal progesterone in pregnancy.

Authors:  Rupsa C Boelig; Athena F Zuppa; Walter K Kraft; Steve Caritis
Journal:  Am J Obstet Gynecol       Date:  2019-06-15       Impact factor: 8.661

6.  In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.

Authors:  Caitlin C Murphy; Piera M Cirillo; Nickilou Y Krigbaum; Barbara A Cohn
Journal:  Am J Obstet Gynecol       Date:  2021-11-09       Impact factor: 10.693

7.  Developmental exposure to 17α-hydroxyprogesterone caproate impairs adult delayed reinforcement and reversal learning in male and female rats.

Authors:  Rebecka O Serpa; Christine K Wagner; Ruth I Wood
Journal:  J Neuroendocrinol       Date:  2020-06-02       Impact factor: 3.627

8.  Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.

Authors:  Amy-Eunice Furcron; Roberto Romero; Olesya Plazyo; Ronald Unkel; Yi Xu; Sonia S Hassan; Piya Chaemsaithong; Arushi Mahajan; Nardhy Gomez-Lopez
Journal:  Am J Obstet Gynecol       Date:  2015-08-08       Impact factor: 8.661

9.  Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: clinical and public health implications.

Authors:  Agustin Conde-Agudelo; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2015-10-09       Impact factor: 8.661

Review 10.  17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.

Authors:  C A Combs; E Schuit; S N Caritis; A C Lim; T J Garite; K Maurel; D Rouse; E Thom; A T Tita; Bwj Mol
Journal:  BJOG       Date:  2015-12-10       Impact factor: 6.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.